President Joe Biden recently gave an update on his treatment for metastatic prostate cancer. A urologist explains ways to ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low ...

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved substantially over the past decade, with androgen receptor pathway inhibitors, taxanes, poly ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...

At the Texas Medical Center, research on new drugs and treatments are changing survival rates for some of the most difficult ...

A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a study conducted by researchers at Umeå University together with ...